Command Palette

Search for a command to run...

VIJAYA

₹1025.25+0.54%

Market Cap
₹10,528.28 Cr
Stock P/E
69.53
ROCE
30.27%
ROE
19.84%
Book Value
₹81.02

Financials

YoY Net Sales
EPS Growth
Operating Margin

You might have missed

Vijaya Diagnostic Announces Amalgamation with Medinova Services

Corporate Action
10 hours ago

Vijaya Diagnostic Approves Amalgamation with Medinova Services

Corporate Action
10 hours ago

Vijaya Diagnostic Completes Medinova Amalgamation Deal

Corporate Action
10 hours ago

Shareholding

Holdings
Distribution
Promoter
Foreign Investors
Domestic Investors
Public

From Last Concall

POSITIVES
  • •
    Robust top-line growth and Hyderabad expansion driving outperformance
  • •
    Strong profitability with healthy EBITDA and PAT margins
NEGATIVES
  • •
    Hubs cause short-term drag, mitigated by operating leverage
  • •
    Management cannot provide margin guidance for new centers

Peers Summary

Sector Leader

Vijaya Diagnostic Centre Ltd. stands out in the Hospital & Healthcare Services sector with impressive revenue growth and profitability metrics, positioning it as a sector leader. Despite its high valuation, it boasts solid operational efficiency and significantly lower debt levels compared to some peers, making it a strong contender for investors seeking growth and stability.

Key Points
  • • Vijaya Diagnostic Centre Ltd. shows the highest revenue YoY growth at 24.39% among peers.
  • • Aster DM Healthcare Ltd. is the best value pick with a low PE of 5.05 and decent profitability metrics.
  • • Fortis Healthcare Ltd. is financially risky, indicated by its extremely high PE ratio of 1094.63 and low ROE.
Top Performers
Vijaya Diagnostic Centre Ltd.

Highest revenue growth YoY (24.39%) and solid ROE (19.96%).

Narayana Hrudayalaya Ltd.

Strong ROE of 24.27% and good EPS growth.

Global Health Ltd.

Strong revenue growth (21.56%) and solid profitability metrics.

Leveling the playing field in markets.

© 2025 EQHQ Technologies Pvt Ltd

"Information provided is for educational purposes only and not financial advice.

Explore
Watchlists